HopeStage
Back to all studies
CompletedNCT02832037

BI 425809 for Cognition and Daily Function in Schizophrenia

About this titleRead the official source — NCT02832037
Medication studyAges 18–50Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
Garden Grove and 80 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 25, 2016
Recruitment status
Completed
Enrollment listed in the registry
509
Sponsor
Boehringer Ingelheim
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Canada, United Kingdom, ...
Age range
From 18 Years to 50 Years
Official registry ID
NCT02832037
Official title
Show the full official title

A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Garden Grove, United States · Lemon Grove, United States · Orange, United States

68 more locations
  • Panorama City, United States
  • Pico Rivera, United States
  • San Diego, United States
  • Miami, United States
  • Atlanta, United States
  • Chicago, United States
  • Lake Charles, United States
  • Ann Arbor, United States
  • St Louis, United States
  • Buffalo, United States
  • Cedarhurst, United States
  • Rochester, United States
  • Raleigh, United States
  • Dayton, United States
  • DeSoto, United States
  • Salt Lake City, United States
  • Bellevue, United States
  • Innsbruck, Austria
  • Vienna, Austria
  • Penticton, Canada
  • Vancouver, Canada
  • Chatham, Canada
  • Toronto, Canada
  • Montreal, Canada
  • Bad Homburg, Germany
  • Berlin, Germany
  • Leipzig, Germany
  • Mannheim, Germany
  • Westerstede, Germany
  • Concesio (BS), Italy
  • Milan, Italy
  • Orbassano (TO), Italy
  • Aichi, Toyoake, Japan
  • Chiba, Chiba, Japan
  • Chiba, Ichikawa, Japan
  • Fukuoka, Kitakyushu, Japan
  • Hokkaido, Sapporo, Japan
  • Hyogo, Kobe, Japan
  • Kagawa, Kita-gun, Japan
  • Kanagawa, Kawasaki, Japan
  • Nara, Kashihara, Japan
  • Osaka, Moriguchi, Japan
  • Tokushima, Anan, Japan
  • Tokyo, Kodaira, Japan
  • Tokyo, Setagaya, Japan
  • Tokyo, Shinjuku-ku, Japan
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Leszno, Poland
  • Szczecin, Poland
  • Torun, Poland
  • Warsaw, Poland
  • Gwangju, South Korea
  • Incheon, South Korea
  • Seongnam, South Korea
  • Seoul, South Korea
  • Barcelona, Spain
  • Madrid, Spain
  • Majadahonda (Madrid), Spain
  • Salamanca, Spain
  • Santander, Spain
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Dudley, United Kingdom
  • Edinburgh, United Kingdom
  • Glasgow, United Kingdom
  • London, United Kingdom
  • Truro, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Did this study involve medication?

Yes. The study involved medication, including BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies